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The composition of the gastrointestinal microbiota and
associated metabolites changes dramatically with diet
and the development of obesity. Although many corre-
lations have been described, speciﬁc mechanistic links
between these changes and glucose homeostasis re-
main to be deﬁned. Here we show that blood and in-
testinal levels of the microbiota-produced N-formyl
peptide, formyl-methionyl-leucyl-phenylalanine, are ele-
vated in high-fat diet–induced obese mice. Genetic or
pharmacological inhibition of the N-formyl peptide recep-
tor Fpr1 leads to increased insulin levels and improved
glucose tolerance, dependent upon glucagon-like peptide
1. Obese Fpr1 knockout mice also display an altered
microbiome, exemplifying the dynamic relationship be-
tween host metabolism and microbiota. Overall, we de-
scribe a newmechanism by which the gut microbiota can
modulate glucose metabolism, providing a potential ap-
proach for the treatment of metabolic disease.
Chronic inﬂammation in obesity can induce insulin re-
sistance leading to type 2 diabetes (T2D) (1). The com-
mensal microbiota of the gastrointestinal (GI) tract serve
as a key link between diet and metabolism, producing
numerous metabolites that inﬂuence host physiology
(2,3). Changes in gut microbiota, termed dysbiosis, are
associated with obesity as well as other disease states.
Interestingly, obesity-associated dysbiosis has been impli-
cated in the development of insulin resistance and T2D (4).
As of yet, most studies that have linked dysbiosis with
obesity or T2D involve associations and correlations with-
out detailed mechanisms. As rates of obesity and T2D
continue to rise across the globe (5), the identiﬁcation of
the mechanisms by which gut microbiota interact with the
host to modulate metabolism is necessary before thera-
peutic interventions can be developed.
The effects of the microbiome and microbiota-derived
byproducts extend beyond the local intestinal epithelium
or gut immune cells. In mice fed a high-fat diet (HFD), gut
dysbiosis preceded elevations in circulating inﬂammatory
cytokines, suggesting an early role of the microbiome
in the induction of inﬂammation (6). As well, an “obese”
microbiome signature confers an increased capacity to
harvest energy from the diet, which could contribute to
the obese state (7). Obesity is strongly associated with an
increased microbiome content of the Firmicutes phylum
and a decreased representation of the Bacteroidetes phylum
(8). The importance of the microbiome was further high-
lighted in a study where germ-free (GF) mice that received
microbiota transplants from an obese human twin gained
10% more fat mass compared with mice receiving a micro-
biota transplant from the lean twin (9). However, the
mechanisms connecting microbiome changes and insu-
lin resistance or obesity remain to be elucidated, and are
likely to involve both immune cells and enteroendocrine
cells (10).
Incretins are a class of metabolic hormones released
from enteroendocrine cells in the gut (11). After eating,
glucagon-like peptide 1 (GLP-1) is released from L cells,
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which act on b-cells to potentiate glucose-stimulated in-
sulin secretion (11). Indeed, antagonism of the GLP-1
receptor (Glp1r) lowers insulin secretion and increases
blood glucose concentrations (12). In T2D humans, post-
prandial GLP-1 secretion is generally impaired (13), al-
though the mechanism has not been established (14). The
microbiome, including metabolites and byproducts, may
play a role in gut hormone secretion since enteroendocrine
cells contain receptors to these products and can be
inﬂuenced by them (10).
Metabolites and byproducts of the microbiome have
been shown to orchestrate a variety of immune responses
in the mammalian host. Among these different products,
N-formyl peptides are derived from foreign bacteria or
destroyed host cells (mitochondria) and activate G-protein–
coupled N-formyl peptide receptors (FPRs) (15). N-formyl
peptides traditionally deﬁne a large group of oligopeptides
that contain a formyl-containing methionine (16). These
motifs are part of a larger group known as pathogen- or
danger-associated molecular patterns because they stimu-
late immune responses and inﬂammation (17). N-formyl
peptides can stimulate chemotaxis of FPR-expressing im-
mune cells (18), which leads to a signaling cascade that can
cause phagocytosis (19) or apoptosis (20). Intestinal epi-
thelial cells also express the Fpr1 receptor and, in response
to an infection, can affect epithelial cell restitution (21) or
migration (22). However, a role for Fpr1 in metabolism
remains unexplored (23).
In the current study, we investigated whether formyl-
methionyl-leucyl-phenylalanine (fMLF) levels are altered
in conditions of obesity and the associated dysbiosis, and
reveal a mechanism whereby this bacterial product inﬂu-
ences glucose metabolism.
RESEARCH DESIGN AND METHODS
Animal Care and Use
Frp1 knockout (Frp1-KO) and Glp1r-KO mice were gen-
erated as previously described (24,25). Only male mice
were used in this study, fed ad libitum and maintained on
a 12-h light/dark cycle. At 8 weeks of age, mice were placed
on a 60%HFD (Research Diets) or normal chow diet (NCD)
(13.5% fat; LabDiet) for 8–10 weeks before analyses. For
broad-spectrum antibiotic treatment, mice were subject to
daily oral gavage (OG) for 2 weeks with water alone or
containing a mixture of antibiotics (Sigma-Aldrich): 0.5
mg/mL vancomycin HCl, 1 mg/mL ampicillin sodium salt,
1 mg/mL neomycin sulfate, 1 mg/mL metronidazole, and
1 mg/mL gentamycin sulfate. Mice were treated with the
Glp1r antagonist exendin 9-39 (Sigma-Aldrich) or saline
vehicle in a 0.2 mg/kg dose 20 min before metabolic
studies. fMLF (Sigma-Aldrich) was administered at
1 mg/kg in saline via OG 1 h prior to analyses. Cinnamoyl-
phenylalanyl-(D)leucine-phenylalanyl-(D)leucine-phenylalanine
(cFLFLF) was provided daily at 0.5 mg/kg by OG for 2 weeks
prior to analyses. For all drug treatments, body weight
and food intake were monitored prior to and during the
treatment period. GF C57BL/6 mice maintained in the
UC San Diego Gnotobiotic Mouse Facility. GF mice were
fed either an autoclaved chow diet (2019S Teklad Global
19% Protein Extruded Rodent Diet; Harlan Laboratories)
or an irradiated sterilized 60% HFD (06414 Teklad), as
previously described (26). For fecal transplantation, 8- to
10-week-old GF mice were gavaged with fecal suspensions
from eitherWTHFD or Fpr1-KOHFD animals (50 mg/mL).
Animal housing and procedures were performed according
to UC San Diego and Institutional Animal Care and Use
Committee–approved protocols, and conformed to the
Guide for Care and Use of Laboratory Animals of the National
Institutes of Health (NIH).
fMLF Detection and Analysis
Tissues, feces, and plasma were collected, homogenized
and lyophilized, if necessary. Metabolites were extracted
by adding PBS containing 4 nmol/L isotopically labeled
fMLF (N-formyl-L-methionyl-L-leucyl [13C-6, 15N]-L-
phenylalanine) as an internal standard (New England Pep-
tide). The mixture was extracted using a Waters Oasis HLB
SPE cartridge (30 mg, 1 mL) then eluted. The eluent was
dried in vacuo using a Thermo Savant vacuum concentrator
(Thermo Fisher Scientiﬁc) with the resulting dried pellet
resuspended in MeOH:H2O (40:60, v/v) for liquid
chromatography-mass spectrometry (MS) analysis.
Liquid chromatography-MS analysis was performed on
Agilent 1290 Inﬁnity II UPLC system (Agilent Technolo-
gies) coupled to an Agilent 6495 triple-quadrupole mass
spectrometer equipped with an electrospray ionization
source. The acquired data were analyzed by Agilent Mass-
Hunter workstation software (version B.07.01), and the
concentration of fMLF was determined using calibration
curves of isotopically labeled standard spiked into pooled
plasma or stool at 1, 2.5, 5, 10, 25, and 50 nmol/L.
Bacterial DNA Measurement From Feces
The PowerViral DNA/RNA Isolation Kit (MoBio) was used
to isolate DNA from feces, followed by quantitative PCR
(qPCR) for the bacterial 16S rRNA gene V2 region. Bac-
terial DNA concentration was estimated using a standard
curve of bacterial DNA.
Cell Culture and siRNA Transfection
Intraperitoneal macrophages were elicited from mice by
injection of 3% thioglycollate and harvested in PBS after
3 days. mGLUTag cells were cultured as previously de-
scribed (27). Forty-eight hours after plating cells, we
transfected pooled siRNA libraries against Fpr1 or Fpr2,
or a scrambled negative control (ON-TARGETplus SMART-
pool; Dharmacon), using GenMute Transfection Reagent
(SignaGen Laboratories).
In Vitro Chemotaxis Assay
After siRNA transfection, 1 3 105 cells were placed in the
upper chamber of a Transwell plate (8 mm polycarbonate
ﬁlter; Corning), whereas RPMI medium containing fMLF
(250 nmol/L) (Sigma-Aldrich) or MCP-1 (100 ng/mL)
(Sigma-Aldrich) was placed in the lower chamber, and
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incubated for 4 h. Cells that migrated to the other side of
the Transwell ﬁlter were stained with DAPI, images cap-
tured on an Olympus MVX10 MacroView Microscope and
cells counted using ImageJ software (NIH).
Gene Expression Analysis
RNA was isolated with the DirectZol RNA isolation kit
(Zymo Research), and cDNA synthesized using the Ap-
plied Biosystems High Capacity Reverse Transcription Kit
(Thermo Fisher Scientiﬁc). Quantitative real-time PCR
was performed using iTaq SYBR Green Supermix (BIO-
RAD) and the Applied Biosystems StepOnePlus Real-Time
PCR System (Thermo Fisher Scientiﬁc). Relative gene
expression was calculated using the DDCt method with
GAPDH as an internal control. Inferred expression of
intestinal epithelial cell Fpr1 was calculated by subtracting
lamina propria gene expression from the total ileum gene
expression. Primer sequences are listed in Supplementary
Table 1.
Intracellular cAMP Analysis
Intracellular cAMP levels in intraperitoneal macrophages
were measured using the Bridge-It cAMP Designer Fluo-
rescence Assay Kit (Mediomics).
Metabolic Studies
Mice were fasted for 6 h prior to conducting insulin
tolerance tests and glucose tolerance tests (GTTs), which
have been described previously (28).
GLP-1 Detection
Blood serum was collected from mice fasted for 6 h,
immediately before (basal) and 10–15 min after dextrose
gavage, in the presence of DPP-4 (dipeptidyl peptidase 4)
inhibitor (EMD Millipore). Postprandial blood collection
was performed 10 min after gavage in NCD mice and
15 min after gavage in HFD mice. Analysis of GLP-1 was
conducted by High Sensitivity GLP-1 Active ELISA Kit,
Chemiluminescent (Millipore Sigma).
Glucose-Stimulated Insulin Secretion Assay
Primary murine islets were isolated as previously described
(29). Secreted insulin was normalized to the corresponding
intracellular insulin levels in the cell pellet of each sample.
Glucose-Stimulated GLP-1 Secretion Assay
mGLUTag cells were stimulated with 3 mmol/L glucose in
the presence or absence of Fpr1 agonists (fMLF) for 4 h.
Plasma Protein Measurements
Fasting insulin, glucagon, total GLP-1, and active GLP-1
levels were measured by ELISA (Alpco, Mercodia, and EMD
Millipore, respectively). Other fasting plasma proteins were
measured by MILLIPLEX Multiplex Assay (EMD Millipore).
Histological Analyses
Tissue sections of pancreas, epididymal white adipose tissue
(eWAT), small intestine, or colon were immunostained with
appropriate antibodies, which are listed in Supplementary
Table 1 and were analyzed as described previously (30).
RNA Fluorescence In Situ Hybridization
RNA ﬂuorescence in situ hybridization was performed on
frozen sections of the small intestine and colon using an
RNAscope Fluorescent Multiplex Kit with RNAscope
probes designed against mouse Fpr1 (catalog #319251)
and mouse Proglucagon (catalog #400601), according to the
manufacturer instructions (Advanced Cell Diagnostics,
Inc.). Slides were counterstained with DAPI, and images
were captured with an Olympus FV1000 Spectral Confocal
Microscope. For quantiﬁcation, 15–30 randomly selected
Proglucagon+ L cells on each slide were observed for the
Fpr1 probe signal, and images were analyzed for Fpr1
probe ﬂuorescence intensity using ImageJ software.
Immunoblot Analysis
Proteins from tissue lysates loaded onto an SDS-PAGE gel
then transferred to a polyvinylidene ﬂuoride membrane.
Membranes were blocked then incubated with antibodies,
which are listed in Supplementary Table 2 and were
analyzed as previously described (21).
Flow Cytometry Analysis
Lamina propria leukocytes were isolated from the small
intestine and colon as previously described, followed by
staining with ﬂuorescence-tagged antibodies to detect cell
lineages (see table in Goodyear et al. [31]) (Supplementary
Table 2). Data were collected with a BD FACSCanto ﬂow
cytometer (BD Biosciences) and analyzed using FlowJo
software.
Fecal Albumin Analysis
Fecal pellets were collected prior to and 8–10 weeks after
placing animals on an HFD and were frozen at 280°C.
Feces were resuspended at 10 mg/mL in PBS, and the
albumin concentration determined by ELISA (Bethyl Lab-
oratories, Inc).
In Vivo FITC-Dextran Assay
Analysis was performed as previously described (32). The
concentration of FITC-dextran was determined by ﬂuo-
rescence spectroscopy relative to a linear standard curve of
FITC-dextran prepared in plasma from untreated mice.
Bacterial 16S rRNA Gene Sample Processing and
Sequencing
Bacterial DNA was isolated from feces using the Power-
Fecal DNA Isolation Kit (MoBio), according to the man-
ufacturer guidelines. Pools of PCR ampliﬁcation using
bacterial 16S V4 rDNA fusion primers (515f and 806r)
were loaded into an Illumina MiSeq and sequenced for
250 cycles for paired-end sequencing (33).
Sequencing Data Analyses
Sequenced paired-end reads were merged, quality ﬁltered,
and dereplicated with USEARCH (34). Representative
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sequences from the de novo operational taxonomic units
(OTUs) were assigned taxonomic classiﬁcation via mothur’s
Bayesian classiﬁer at 80% conﬁdence; the classiﬁer was
trained against the GREENGENES reference database of
16S rRNA gene sequences clustered at 99% (35). The a-
and b-diversity metrics were calculated as previously de-
scribed (36,37).
Inference of Metagenomes
Metagenome prediction was conducted from 16S rRNA
sequencing data using the Piphillin algorithm, using
the reference genome databases KEGG 70.1 and BioCyc
18.0 (38).
Synthesis and Puriﬁcation of cFLFLF
The synthetic peptide cFLFLF was synthesized using
a standard solid-phase Wang resin supported Fmoc
(ﬂuorenylmethyloxycarbonyl) peptide synthesis proto-
col using an auto synthesizer (CSBio), similar to pre-
vious publications (39).
Signiﬁcance Testing
Sample sizes necessary for animal studies were estimated
using Russ Lenth’s power calculator (University of Iowa,
Iowa City, IA [http://homepage.divms.uiowa.edu/;rlenth/
Power/]). Whole microbiome signiﬁcance testing was per-
formed by permutational ANOVA (PERMANOVA, version
3.2.2 [www.r-project.org]) (40). Taxon signiﬁcance, or the
univariate differential abundance of OTUs, was tested using
the DESeq2 package, and q values were calculated with the
Benjamini-Hochberg procedure to correct P values, control-
ling for false discovery rates (41,42). All other data were
analyzed for signiﬁcance testing using GraphPad Prism
software.
RESULTS
fMLF Is Increased in HFD/Obese Mice and Requires
Fpr1 to Induce Chemotaxis
To determine whether levels of N-formyl peptides are
altered by HFD-induced obesity, we conducted MS analysis
of blood plasma and GI tissues from wild-type (WT) mice
fed either a NCD or a 60%HFD. We found that blood levels
of the N-formyl peptide fMLF are several fold higher in
obese/HFD animals compared with lean/NCD animals, and
increase over time with animals being fed an HFD (Fig. 1A
and B). GI levels of fMLF across all gut regions are even
more dramatically increased while being fed an HFD and
are in a much higher range compared with those found in
the circulation (Fig. 1C and E). These elevated fMLF levels
are particularly dramatic considering the reduction in total
bacterial load that occurs over time while on an HFD (Fig.
1F). Consistent with a microbiota-derived origin, treat-
ment of NCD or HFD mice with broad-spectrum anti-
biotics for 2 weeks led to an;80–100% reduction in blood
and intestinal fMLF levels (Fig. 1G and H). Additionally,
GF animals also had barely detectable intestinal and blood
levels of fMLF on NCD (Supplementary Fig. 1A and B). One
of the receptors for fMLF is the N-formyl receptor, Fpr1,
which we found expressed in all parts of the intestine and
is increased in the ileum and colon under HFD feeding (Fig.
1I). Intestinal lamia propria showed the highest expression
of Fpr1 (Supplementary Fig. 1C). However, Fpr1 expres-
sion was ;50% reduced in the small intestinal lamina
propria of HFD animals; therefore, the increased Fpr1
expression in the total intestinal tissue in these mice
resides in the epithelial compartment (Supplementary
Fig. 1D). Although mammals have several FPRs, in vitro
macrophage chemotaxis experiments revealed that fMLF
acts through the Gi-coupled Fpr1, rather than Fpr2, and
also reduces forskolin-induced cAMP (Fig. 1J–L and Sup-
plementary Fig. 1E and F) (43). In addition, qPCR expres-
sion analyses conﬁrmed that Fpr1 is expressed throughout
the intestine, where fMLF levels are highest, and is in-
creased in HFD animals compared with NCD animals
(Supplementary Fig. 1G and H). These ﬁndings, together
with the marked differences between blood and intestinal
fMLF levels, led us to suggest that Fpr1 is stimulated by
fMLF present in the intestinal lumen, which is consistent
with reports that Fpr1 is expressed on the apical surface of
intestinal epithelial cells (44).
Loss of Fpr1 in HFD/Obese Mice Improves Glucose
Tolerance and Is GLP-1 Dependent
To assess the metabolic effects of Fpr1, we placed WT and
Fpr1-KO littermates on an HFD for 10 weeks and mea-
sured glucose and insulin tolerance. OG-GTTs revealed
a signiﬁcant improvement in glucose tolerance in Fpr1-KO
versus WT mice, with no change in body weight, organ
weight, or overall food intake (Fig. 2A and B and Supple-
mentary Fig. 2A–I). In addition, Fpr1-KO mice displayed
increased plasma insulin levels in both the basal state and
in response to glucose (Fig. 2C), while insulin tolerance
tests revealed no improvement in insulin sensitivity (Fig.
2D and E). In contrast, the loss of Fpr1 did not lead to
a signiﬁcant improvement in glucose or insulin tolerance
on NCD (Supplementary Fig. 3). Overall, this is consistent
with the idea that elevated fMLF levels in the HFD state
activates Fpr1 leading to glucose intolerance.
To examine how loss of Fpr1 leads to increased insulin
levels, we measured ex vivo glucose-stimulated insulin
secretion using pancreatic islets isolated from HFD WT
and Fpr1-KO mice. Surprisingly, we found no change in
insulin secretion (Fig. 2F). In addition, islet size and total
mass in Fpr1-KOmice was unchanged (Supplementary Fig.
2J and K), although intracellular levels of insulin were
elevated (Fig. 2G). This suggests that Fpr1 deﬁciency
increases insulin levels through an extrinsic, or islet-
nonautonomous, manner. This is also consistent with
ﬁndings that Fpr1 is expressed only at very low levels in
WT pancreatic islets and is reduced further in HFD con-
ditions (Supplementary Fig. 1D). Interestingly, circulating
GLP-1 levels were higher in HFD Fpr1-KO mice compared
with WT mice (Fig. 2H). No signiﬁcant changes were detected
in levels of other circulating gastric hormones or glucagon
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(Supplementary Fig. 4), suggesting that GLP-1 may drive
the increased insulin secretion in Fpr1-KO animals. We
also found that antibiotic-treated HFD mice displayed
improved glucose tolerance and increased GLP-1 levels,
consistent with a connection between the gut microbiota
and GLP-1 modulation (Supplementary Fig. 5). To deter-
mine whether the glucose-tolerant phenotype of HFD
Fpr1-KO mice is dependent upon GLP-1, we pretreated
WT and Fpr1-KO HFD mice with the Glp1r antagonist
exendin 9-39 (45). This antagonist prevented the improved
Figure 1—fMLF is increased in HFD/obese mice and requires Fpr1 for chemotaxis. A: Blood plasma fMLF levels in lean/NCD vs. obese/HFD
mice after 16 weeks on an HFD (n = 8–12 mice/group). B: Timecourse of fMLF levels after placement on an HFD (n = 6–8mice per time point).
C: fMLF levels in various intestinal tissues in WT NCD and HFD animals after 8 weeks on diet (n = 8 mice/group). Ileum (D) and colon (E ) fMLF
levels after 8 and 20weeks of HFD or NCD (n = 6–8mice/group). F: Bacterial DNA levels in colon fecal samples, determined by 16S rRNAgene
expression and presented as ameasure of bacterial load (n = 8mice/group).G: Blood plasma fMLF levels in NCDandHFDmice (after 8weeks
on diet) treated with or without antibiotics (n = 6–8 mice/group). H: Ileum fMLF levels in HFD antibiotic-treated animals, after 8 weeks on diet
(n = 4 mice/group). I: Relative Fpr1 transcript levels in various intestinal tissues of NCD and HFD WT animals after 8 weeks on diet (n =
8 mice/group). J: Chemotaxis assays of thioglycollate-elicited intraperitoneal macrophages (IP-Macs) in response to fMLF treatment
(250 nmol/L), and after siRNA knockdown of Fpr1 or Fpr2 (n = 3). K: Chemotaxis assays in response to MCP-1 treatment (100 ng/mL)
demonstrate that knockdown of Fpr1 does not inhibit macrophage activation by other chemokines. L: mRNA transcript levels of Fpr1 and
Fpr2 in IP-Macs after siRNA knockdown. #Below detection limit. Data are mean 6 SEM. ns, not signiﬁcant. *P , 0.05, **P , 0.001, ***P ,
0.0001 by one-way ANOVAwith Bonferroni post-test (D–G) or two-tailed t test comparing the indicated groups. InD–F, statistical signiﬁcance
is indicated by comparing groups at each respective time point.
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glucose tolerance in Fpr1-KO mice compared with vehicle-
treated littermates (Fig. 2I and J). Similarly, the elevated
insulin levels in Fpr1-KO animals were suppressed by Glp1r
inhibition (Fig. 2K). Thus, the beneﬁcial effects of Fpr1
deﬁciency are dependent upon GLP-1 signaling.
GLP-1 Secretion Is Dependent on Fpr-1 Expression
Consistent with elevated GLP-1 levels in HFD Fpr1-KO
mice, immunoﬂuorescence analysis revealed increased
GLP-1 expression in enteroendocrine L cells of the ileum
and colon in these mice compared with reduced levels
observed in WT HFD mice (Fig. 3A and B and Supplemen-
tary Fig. 6A). mRNA transcript levels of Proglucagon, the
precursor of GLP-1, were also increased in Fpr1-KO mice
relative toWTmice on an HFD (Fig. 3C and Supplementary
Fig. 6B and C), indicating a potential transcriptional basis
for increased GLP-1 levels. We also demonstrate Fpr1
expression in L cells through RNA ﬂuorescence in situ
hybridization and immunoﬂuorescence analyses (Fig. 3D
and Supplementary Fig. 6D and E). Interestingly, whereas
Fpr1 expression was quite low and difﬁcult to detect in
NCD L cells, we found increased Fpr1 expression in HFD L
cells. In addition, Fpr1 expression was increased in the
colon of HFDmice, as measured by qPCR and Western blot
analyses (Fig. 1I and Supplementary Figs. 1G and 6D–G).
This provides a reasonable explanation for the more
Figure 2—Loss of Fpr1 in HFD/obese mice improves glucose tolerance and is GLP-1 dependent. A and B: OG-GTT after 10 weeks on an
HFD, and area under the curve (AUC) (n = 7–10mice/group).C: Plasma insulin levels duringOG-GTT.D andE: Intraperitoneal insulin tolerance
test after 12 weeks on an HFD and AUC (n = 7–10mice/group). F andG: Glucose-stimulated insulin secretion and intracellular insulin levels in
pancreatic islets from HFDWT and Fpr1-KOmice (n = 4mice/per group, 20 islets/incubation).H: Active GLP-1 levels during the OG-GTT in A
(n = 24–25mice/group). I and J: OG-GTT and corresponding AUCofWT and Fpr1-KOHFDmice after 10 weeks on an HFD and treatment with
or without the Glp1r antagonist exendin 9-39 (n = 10–11 mice/group). K: Plasma insulin levels during the OG-GTT in I (n = 10–11mice/group).
Error bars indicate the SEM. ns, not signiﬁcant. *P, 0.05, **P, 0.001, ***P, 0.0001 by two-way ANOVA and Bonferroni post-test (A and I),
one-way ANOVA and Bonferroni post-test (J) or two-tailed t test. Statistical signiﬁcance is indicated comparing groups at each respective
time point. In I and K, signiﬁcance is indicated for WT vs. Fpr1-KO animals treated with vehicle.
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dramatic phenotypic difference in Fpr1-KO mice on an
HFD. GLP-1 can also be produced in pancreatic a-cells, but
our studies show that Fpr1 expression is very low in
isolated murine islets, with even lower expression in
HFD (Supplementary Fig. 1C andD). This suggests that the
actions of Fpr1 to modulate GLP-1 levels are primarily
through L cells in the intestine.
Given these results, we postulated that fMLF acts upon
L cells to suppress glucose-stimulated GLP-1 secretion. To
test this, we measured glucose-stimulated GLP-1 secretion
in murine mGLUTag L cells, treated with or without fMLF.
Treatment with fMLF suppressed GLP-1 secretion in
a dose-dependent fashion (Fig. 3E). Furthermore, siRNA-
mediated Fpr1 knockdown abrogated the effect of fMLF
to reduce GLP-1 secretion at any of the concentrations
tested (Fig. 3F and Supplementary Fig. 6F). Whereas Fpr1
was well expressed, we could not detect the low-afﬁnity
Fpr2 in these cells (data not shown). Treatment of mGLUTag
cells with palmitate to mimic HFD conditions also led
to increased expression of Fpr1, similar to that observed
in vivo (Supplementary Fig. 6E). Overall, we conclude that
fMLF can signal through FPR1 in L cells to inhibit GLP-1
secretion.
Flow cytometric analysis of the small intestinal lamina
propria conﬁrmed previously reported immune cell pop-
ulation differences in HFD versus NCD animals, including
reduced eosinophil and increased macrophage numbers
(Supplementary Fig. 7A–H) (32). However, loss of Fpr1
did not change immune cell composition in either diet
condition. qPCR analysis of these cells revealed little
change in proinﬂammatory gene expression, although anti-
inﬂammatory interleukin-10 expression was increased in
Fpr1-KO HFD mice (Supplementary Fig. 7I and J). Sim-
ilarly, elevated interleukin-10 levels were detected in the
blood of these mice (Supplementary Fig. 7K). Analysis of
inﬂammation in eWAT also showed no signiﬁcant change
in macrophage numbers and only a modest improvement
in inﬂammatory gene expression (Supplementary Fig. 8).
Pharmacological Control of Fpr1 Activity Modulates
GLP-1 Levels and Glucose Tolerance
To conﬁrm that the Fpr agonist fMLF detrimentally
impacts glucose metabolism in vivo, we acutely treated
WT HFD mice with fMLF. Treatment reduced glucose
tolerance (Fig. 4A–C) and GLP-1 levels (Fig. 4D). In con-
trast, fMLF had no signiﬁcant effect in NCD mice, likely
Figure 3—GLP-1 secretion is dependent on Fpr-1 expression. A: Immunoﬂuorescence labeling of GLP-1 in L cells of WT and Fpr1-KO HFD
mouse colon sections (representative images; scale bars = 50 mm; 16 weeks on an HFD). B: Quantiﬁcation of A, including NCD controls (n =
14–20/group). C: ProglucagonmRNA levels in the ileum of WT and Fpr1-KO mice, relative to WT NCD (n = 8, 16 weeks on an HFD). D: RNA
ﬂuorescence in situ hybridization of Proglucagon and Fpr1 in colonic L cells (representative images; scale bars = 10 mm) (n = 6/group). E and F:
Glucose-stimulated GLP-1 secretion in mGLUTag cells treated with scrambled control siRNA (E ) or Fpr1 siRNA (F ) and different
concentrations of fMLF (n = 5). Error bars indicate SEM. ns, not signiﬁcant. *P , 0.05, **P , 0.001, ***P , 0.0001 by one-way ANOVA
and Bonferroni post-test, comparing the indicated groups.
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due to the low expression of GI L-cell Fpr1 in these animals
compared with HFD animals (Supplementary Fig. 9A). In
addition, we determined whether pharmacological inhibi-
tion of Fpr1 could provide beneﬁts similar to those seen in
Fpr1-KO mice. In contrast to agonist administration, the
treatment of WT HFD mice with the Fpr1 antagonist
cFLFLF (Supplementary Fig. 9B) improved glucose toler-
ance (Fig. 4E and F) and increased plasma insulin and GLP-
1 levels, without changing body weight or food intake (Fig.
4G and H and Supplementary Fig. 9C–H). The improved
glucose tolerance induced by the Fpr1 antagonist is de-
pendent upon the Glp1r, as treatment had no effect in
HFD Glp1r-KO littermates (Fig. 4E and F). These results
suggest that GLP-1 dependency is the dominant mecha-
nism for the Fpr1-KO phenotype.
Loss of Fpr1 Alters Intestinal Microbiome Composition
in HFD/Obese Mice
We next assessed the effects of diet and genotype on the
microbiome. Levels of fMLF in the blood and intestine of
HFD Fpr1-KO mice were reduced compared with WT mice
(Fig. 5A and B). Measurement of GI permeability as
assessed by fecal albumin content and analysis of blood
levels of orally administered FITC-dextran conﬁrmed in-
creased permeability in HFD animals, consistent with the
increased plasma fMLF levels (Supplementary Fig. 10A and
B) (32). However, we found no change in GI permeability in
Fpr1-KO mice compared with WT mice, suggesting that
the microbiota composition in the Fpr1-KO mice might be
responsible for decreased fMLF. To investigate this, we
conducted fecal 16S rRNA gene sequencing of WT mice and
Fpr1-KO littermates fed a NCD or HFD. Sequences were
clustered based on similarity into OTUs and compared
against a reference 16S rRNA database to identify their
bacterial classiﬁcations (Supplementary Fig. 10C) (35). There
was a modest change in a-diversity between lean/NCD and
HFD animals as measured by either the Shannon diversity
index or OTU richness (Fig. 5C), while the loss of Fpr1 led to
a marked increase in diversity compared withWTmice on an
HFD, although not on a NCD (Fig. 5C and Supplementary
Fig. 10D and E). We next examined compositional differ-
ences between samples, termed b-diversity, based on dis-
similarity of whole microbiome abundance proﬁles, using
Bray-Curtis and principal component analyses. Diet was the
strongest determinant of differences, with HFD and NCD
samples highly dissimilar regardless of genotype (Fig. 5D).
Interestingly, the Fpr1-KO signiﬁcantly affected microbiome
composition, but only in HFD animals, revealing that HFD
interacts with the Fpr1-KO genotype to uncover an other-
wise masked phenotype.
Comparison between Fpr1-KO and WT microbiome
abundances on an HFD revealed differences in .360
OTUs (Fig. 5E and Supplementary Table 3). The mean
relative abundances of several obesity-associated families
within these phyla, including Lachnospiraceae and Rikenel-
laceae (Supplementary Fig. 10F–H) (46), were altered by
diet and genotype. To illuminate what functional bacterial
pathways and enzymes might be altered, we performed
Piphillin inferred metagenomic content analysis, which
predicts metagenomes from 16S rRNA sequencing data
Figure 4—Pharmacological control of Fpr1 activity modulates GLP-1 levels and glucose tolerance. A: OG-GTT of WT HFD mice after acute
OG with the Fpr1 agonist fMLF (1 mg/kg) (n = 6 mice/group, 10 weeks on HFD). B–D: Area under the curve (AUC), insulin levels, and active
GLP-1 levels measured during the OG-GTT. The information for A also applies to C and D. E: OG-GTT of WT and Glp1r-KO mice after
10weeks on anHFD and daily OGof the Fpr1 antagonist cFLFLF for 2weeks (0.5 g/kg) (n = 8mice/group). F–H: AUC, insulin levels, and active
GLP-1 levels measured during the OG-GTT. Information for E also applies to G and H. Data are mean6 SEM. ns, not signiﬁcant. *P, 0.05,
**P , 0.001 by two-way ANOVA and Bonferroni post-test (A and E ), one-way ANOVA and Bonferroni post-test (F ) or two-tailed t test.
Statistical signiﬁcance is indicated comparing groups at each respective time point. In E, G, and H, signiﬁcance is indicated for WT animals
treated with vehicle vs. WT animals treated with antagonist.
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by comparison with reference genome databases (47). This
analysis predicted numerous pathways and enzymes al-
tered by diet or genotype (Fig. 5F, Supplementary Fig. 10I,
and Supplementary Tables 4 and 5).
As changes in host metabolism can inﬂuence gut micro-
biota composition (4), we tested whether the differences in
microbiota observed in HFD Fpr1-KO mice might be the
result or a cause of improved glucose tolerance. Given the
coprophagic nature ofmice, onewould predict that amicro-
biota-dependent effect would be transferrable through
cohousing. We found that even when cohoused, differences
in glucose tolerance were readily observed between gen-
otypes, arguing against microbiome-transferable effects
(Fig. 5G). Analysis of whole microbiome abundance proﬁles
from multiple cohorts containing cohoused or separated
mice showed that, whereas WT and Fpr1-KO mice raised in
separate cages display differences in microbiota composi-
tion, those that are cohoused are more similar or the same
(Supplementary Fig. 10J).
Fecal Microbiota Transfer From Fpr1-KO HFD Donor
Mice to GF Recipient Mice Does Not Alter Glucose
Tolerance Compared With Controls
To further elucidate the role of the microbiome, we
performed fecal microbiota transfer experiments, in which
we transferred microbiota by gavage from either WT or
Figure 5—Loss of Fpr1 alters intestinal microbiome composition in obese/HFD mice. A: fMLF levels in blood plasma (A) and ileum (B) of
Fpr1-KO vs. WT mice after 20 weeks on an HFD (n = 6–11 mice/group). C: Shannon diversity index in fecal 16S rRNA gene-sequencing data
fromWT and Fpr1-KO mice on a NCD and an HFD (n = 6–10 mice/group). The information for C also applies to D. D: Analysis of dissimilarity
between samples or b-diversity. The pairwise Bray-Curtis dissimilarity between samples is represented by a two-dimensional principal
coordinate analysis ordination plot. Samples separate into three clusters based on diet (Axis 1) and genotype (Axis 2). The percentage of
sample variation due to each axis is indicated. E: Log2 fold change of OTU abundances in Fpr1-KO vs. WT mice on an HFD, showing the
50 most signiﬁcantly changed taxa, color coded by phylum. F: Log2 fold change of bacterial enzymes predicted altered by inferred
metagenomics content analysis, according to the Kyoto Encyclopedia of Genes and Genomes (KEGG) orthology (n = 6–10 mice/group).
AICAR-FMT, phosphoribosylaminoimidazolecarboxamide-formyltransferase; PDF, peptide deformylase; purU, formyltetrahydrofolate deformy-
lase; purT, phosphoribosylglycinamide formyltransferase. G: OG-GTT of WT and Fpr1-KO mice after 10 weeks on an HFD, comparing mice
housed separately based on genotype or cohoused. Data are mean6 SEM. ns, not signiﬁcant. *P, 0.05, **P, 0.001, ***P, 0.0001 by one-
way ANOVA with Bonferroni post-test (A and B), two-way ANOVA and Bonferroni post-test (G) or PERMANOVA and DESEq. 2 (C–F ). In G,
signiﬁcance is indicated for WT cohoused vs. Fpr1-KO cohoused animals at each respective time point.
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Fpr1-KO HFD donor mice to GF recipient animals. After
8 weeks on an HFD, no differences in glucose tolerance
were found between animals receiving microbiota from
WT or Fpr1-KO mice (Fig. 6A). Insulin and GLP-1 levels
were also unchanged, suggesting that the altered micro-
biome of Fpr1-KO mice does not transfer the improved
metabolic phenotype (Fig. 6B and C). Rather, the enhanced
glucose tolerance in Fpr1-KO mice appears to be genotype
related. Body weight, epididymal fat, and liver weight were
also unchanged between mice that received WT or Fpr1-KO
HFD microbiome transplants (Fig. 6D–F).
DISCUSSION
In these studies, we identify a bacterial product and host
receptor signaling mechanism that modulates GLP-1 to
inﬂuence metabolism in diet-induced obesity. As such,
fMLF is among the ﬁrst identiﬁed microbiota-produced
compounds increased in obesity, which can directly impair
glucose homeostasis. These data support a model whereby
lean animals have a healthy microbiota producing lower
levels of fMLF, which, together with low Fpr1 expression
in L cells, allows for abundant postprandial GLP-1 secretion.
In contrast, obesity-induced dysbiosis leads to elevated
fMLF levels and increased Fpr1 expression, culminating
in suppressed GLP-1 secretion and reduced glucose toler-
ance (Supplementary Fig. 11).
Incretins are important hormones that stimulate b-cell
glucose-stimulated insulin secretion (11). In particular, GI
L cells produce GLP-1 under the inﬂuence of dietary
glucose as well as other regulatory inputs. Recent studies
have also demonstrated that glucagon-producing a-cells in
the pancreatic islets also produce GLP-1 and that this may
play an important role in stimulating insulin secretion in
neighboring b-cells (48). In addition, with respect to
a-cells versus L cells, our studies found low expression
of Fpr1 in a-cells compared with robust expression in L
cells, along with high local levels of fMLF in the GI tract
(Supplementary Fig. 1C and D). This suggests that the
major physiologic effects of fMLF are on GI L cells. It is also
well known that GLP-1 has robust effects to improve
glucose homeostasis in an insulin-independent manner
(49). Thus, GLP-1 causes decreased a-cell glucagon secre-
tion, delayed gastric emptying, and neuronal signaling
from the gut to the brain that may contribute to modu-
lation of metabolic homeostasis (50). With this paradigm,
the effects of GLP-1 from either a-cells or L cells on the
stimulation of insulin secretion would represent only one
arm of GLP-1 regulation of glucose homeostasis.
Figure 6—Fecal microbiota transfer (FMT) from WT and Fpr1-KO HFD donor mice to GF recipient mice leads to glucose intolerance. A:
OG-GTT of GF mice fed a NCD or placed on an HFD and gavaged with fecal preparations from WT or Fpr1-KO mice fed an HFD (n = 3–4
mice/group; 8 weeks on an HFD). B: Basal insulin levels taken immediately prior to OG-GTTs. C: Active GLP-1 levels. D: Body weight at
the time of OG-GTTs. E: Weight of eWAT. F: Weight of liver. *P, 0.05, **P, 0.001 by two-way ANOVA and Bonferroni post-test (A) or one-
way ANOVA and Bonferroni post-test, comparing the indicated groups. In A, signiﬁcance is indicated for GF vs. HFD + WT FMT animals at
each respective time point.
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Our studies show that feedingmice anHFD had a strong
effect that caused microbiome changes, commonly termed
dysbiosis. In addition to the diet-induced dysbiosis, we
found that Fpr1-KO also led to alterations in the compo-
sition of the microbiota. Interestingly, predicted levels of
methionyl-tRNA formyltransferase (MTFMT), the enzyme
that produces formylmethionine, were increased in WT
HFD versus NCD mice, consistent with increased fMLF
production (51). Furthermore, in Fpr1-KOmice versus WT
mice on an HFD, predicted levels of purine production
enzymes were elevated, potentially decreasing substrate
availability for MTFMT and contributing to the reduced
fMLF levels observed in Fpr1-KO animals (52). Interest-
ingly, in the current study, whereas Fpr1-KO mice dem-
onstrated an altered microbiome, when we did fecal
transplant studies from Fpr1-KO mice into GF WT ani-
mals, we found that the microbiome transplant did not
confer any changes in metabolic status. These data suggest
that the microbiome alterations we observed in the
Fpr1-KO mice are secondary to their improved metabolic
status.
Another important ﬁnding from this study is that HFD
mice display elevated fMLF levels, which are associated
with glucose intolerance and reduced GLP-1 secretion. This
increased fMLF level is likely derived from the microbiome,
as antibiotic treatment of mice abolished blood levels of
fMLF and GF animals also displayed barely detectable
intestinal and blood fMLF levels (Fig. 1G and H and
Supplementary Fig. 1A and B). Although these data suggest
that most of the fMLF present in HFD mice appears to be
microbiome derived, there may be a small contribution
from host mitochondria, which remains to be determined.
Since the treatment of WT and Fpr1-KO mice with the
GLP1 antagonist (9–39) blocked the effects of Fpr1-KO to
improve glucose tolerance, this suggests that the major
aspects of the metabolic phenotype in the KO animals can
be traced back to GLP-1/GLP1R interactions. Furthermore,
treating mice with exogenous fMLF by OG led to wors-
ening of glucose tolerance, whereas the treatment of these
mice with the Fpr1 antagonist cFLFLF markedly im-
proved glucose tolerance with enhanced insulin secretion.
G-protein–coupled receptors have been established as
important regulators of L-cell GLP-1 secretion through
the elevation of intracellular cAMP levels leading to a rise
in intracellular Ca2+ with membrane depolarization (53).
Since Fpr1 is a Gai-coupled G-protein–coupled receptor,
our data are consistent with the proposal that fMLF
signaling through Fpr1 can lower intracellular cAMP levels
by activating Gai (Supplementary Fig. 1F). These lowered
levels of cAMPwould impair membrane depolarization and
reduce GLP-1 secretion. This raises the possibility that
Fpr1 antagonists could eventually be used in the context of
antidiabetic therapy.
In summary, our ﬁndings illustrate a mechanism
whereby the gut microbiota inﬂuences metabolism in obe-
sity (Supplementary Fig. 11). We demonstrate that fMLF
levels are signiﬁcantly increased in HFD mice and that Fpr1
KO improves glucose tolerance and promotes GLP-1 and
insulin secretion. GLP-1 antagonism reverses the beneﬁcial
metabolic effects of Fpr1 KO, indicating a primary role of
incretins in the phenotype. We also found that the treat-
ment of HFD mice with fMLF can exacerbate glucose
intolerance, although antagonizing fMLF with cFLFLF sig-
niﬁcantly improves glucose tolerance. Finally, microbiome
changes occur with an HFD and Fpr1 KO, which highlight
a dynamic host-microbiome relationship. The antidiabetic
effects of fMLF antagonism should be further explored in
order to maximize the incretin effect in patients who have
uncontrolled hyperglycemia.
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